Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Fedrigo, Carlos A ^a   Grivicich, Ivana ^a   Schunemann, Daniel P ^a   Chemale, Ivan M ^b   Santos, Daiane D ^a   Jacovas, Thais ^a   Boschetti, Patryck S ^a   Jotz, Geraldo P ^c   Filho, Aroldo B ^d   da Rocha, Adriana B ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b Serviço de Neurocirurgia do Hospital Beneficência de Porto Alegre   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Glioblastoma; Hsp70; P53; Radioresistance; Spheroids

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EPIDERMAL GROWTH FACTOR; HEAT SHOCK PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; WORTMANNIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MALE; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR SPHEROID; BIOSYNTHESIS; BRAIN TUMOR; DNA DAMAGE; GENE EXPRESSION REGULATION; GLIOMA; METABOLISM; METHODOLOGY; MULTICELLULAR SPHEROID; PATHOLOGY; PHOSPHORYLATION; RADIATION RESPONSE; TIME; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81055124259     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-156     Document Type: Article

References (48)

1. Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol 2009, 19:171-178. 10.1016/j.semradonc.2009.02.005, 19464632.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, . European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
3. Stupp R, Hegi ME, Mason WP, . European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups & National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. 10.1016/S1470-2045(09)70025-7, 19269895, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups & National Cancer Institute of Canada Clinical Trials Group.
4. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 2008, 31:300-305. 10.1097/COC.0b013e31815e3fdc, 18525311.
5. Corcoran A, De Ridder LI, Del Duca D, Kalala OJ, Lah T, Pilkington GJ, Del Maestro RF. Evolution of the brain tumour spheroid model: transcending current model limitations. Acta Neurochir (Wien) 2003, 145:819-824.
6. Dubessy C, Merlin JM, Marchal C, Guillemin F. Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol 2000, 36:179-192. 10.1016/S1040-8428(00)00085-8, 11033305.
7. Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 2008, 3:1172-1184. 10.1002/biot.200700228, 18566957.
8. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?. Int J Radiat Biol 2007, 83:849-871. 10.1080/09553000701727531, 18058370.
9. Wouters BJ. Cell death after irradiation - how, when and why cells die. Basic Clinical Radiobiology 2009, Chapter 3. UK: Hodder Arnold, Joiner M, Van der Kogel AJ, 4.
10. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell Cycle 2007, 6:1995-2000. 10.4161/cc.6.16.4614, 17721076.
11. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006, 13:1017-1026. 10.1038/sj.cdd.4401913, 16557268.
12. Graner MW, Raynes DA, Bigner DD, Guerriero V. Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Sci 2009, 100:1870-1879. 10.1111/j.1349-7006.2009.01269.x, 19659607.
13. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12:675-684. 2933688, 20824044.
14. Lefranc F, Rynkowski M, DeWitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg 2009, 34:3-35. 10.1007/978-3-211-78741-0_1, 19368079.
15. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human gliobastoma genes and core pathways. Nature 2008, 455:1061-1078. 10.1038/nature07385, 2671642, 18772890, Cancer Genome Atlas Research Network.
16. Farr-Jones MA, Parney IF, Petruk KC. Improved technique for establishing short term human brain tumor cultures. J Neurooncol 1999, 43:1-10. 10.1023/A:1006115608103, 10448865.
17. Carlsson J, Yuhas JM. Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res 1984, 95:1-23.
18. Nirmala C, Rao JS, Ruifrok AC, Langford LA, Obeyesekere M. Growth characteristics of glioblastoma spheroids. Int J Oncol 2001, 19:1109-1115.
19. Schmidt M, Bachhuber A, Victor A, Steiner E, Mahlke M, Lehr HA, Pilch H, Weikel W, Knapstein PG. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003, 129:295-302.
20. Neary JT, Zhu Q. Signaling by ATP receptors in astrocytes. Neuroreport 1994, 5:1617-1620. 10.1097/00001756-199408150-00019, 7819532.
21. Greulich H, Erikson RL. An analysis of Mek1 signaling in cell proliferation and transformation. J Biol Chem 1998, 273:13280-13288. 10.1074/jbc.273.21.13280, 9582373.
22. Brondani Da Rocha A, Regner A, Grivicich I, Pretto Schunemann D, Diel C, Kovaleski G, Brunetto De Farias C, Mondadori E, Almeida L, Braga Filho A, Schwartsmann G. Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. Int J Oncol 2004, 25:777-785.
23. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003, 13:507-518.
24. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 2007, 27:7987-8001. 10.1523/JNEUROSCI.2180-07.2007, 17652589.
25. Sneed PK, Gutin PH, Larson DA, Malec MK, Phillips TL, Prados MD, Scharfen CO, Weaver KA, Wara WM. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994, 29:719-727. 10.1016/0360-3016(94)90559-2, 8040017.
26. Gottfried E, Kunz-Schughart LA, Andreesen R, Kreutz M. Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions. Cell Cycle 2006, 5:691-695. 10.4161/cc.5.7.2624, 16582627.
27. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M. BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 2002, 56:43-49. 10.1023/A:1014448721327, 11949826.
28. Storch K, Eke I, Borgmann K, Krause M, Richter C, Becker K, Schrock E, Cordes N. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 2010, 70:3925-3934. 10.1158/0008-5472.CAN-09-3848, 20442295.
29. Hede SM, Nazarenko I, Nister M, Lindstrom MS. Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. J Oncol 2011, 2011:852970. 3010739, 21209724.
30. Yue WY, Yu SH, Zhao SG, Chen ZP. Molecular markers relating to malignant progression in Grade II astrocytoma. J Neurosurg 2009, 110:709-714. 10.3171/2008.3.JNS17459, 19025355.
31. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 2010, 27:95-101. 10.1007/s10014-010-0272-x, 21046311.
32. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996, 67:808-815. 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V, 8824552.
33. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 1999, 5:637-642.
34. Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 2002, 62:1069-1076.
35. Guo H, Choudhury Y, Yang J, Chen C, Tay FC, Lim TM, Wang S. Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate. J Gene Med 2011, 13:26-36.
36. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003, 21:2508-2518. 10.1200/JCO.2003.11.138, 12839017.
37. Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, McCormick F, Haas-Kogan DA. Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene 2001, 20:2826-2835. 10.1038/sj.onc.1204393, 11420694.
38. Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, Protopopov A, Chin L, Depinho RA. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 2010, 24:2194-2204. 10.1101/gad.1924710, 2947771, 20837658.
39. Stegh AH, DePinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle 2011, 10:33-38. 10.4161/cc.10.1.14365, 21200141.
40. Arshad H, Ahmad Z, Hasan SH. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pac J Cancer Prev 2010, 11:1637-1640.
41. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000, 19:3816-3822. 10.1038/sj.onc.1203700, 10949938.
42. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103. 10.1379/CSC-99r.1, 1176476, 16038406.
43. Cai H, Yin S, Ma F, Yu F, Li D, Lv M, Chen Y, Lv Z. ShRNA-mediated gene silencing of Heat shock protein 70 inhibits human colon cancer cell growth in vitro and in vivo. Mol Cell Biochem 2011,
44. Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, Montero E. Radiosensitization of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009, 100:950-958. 10.1038/sj.bjc.6604943, 2661790, 19293809.
45. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008, 98:749-755. 10.1038/sj.bjc.6604222, 2259177, 18253126.
46. Ghosh MK, Sharma P, Harbor PC, Rahaman SO, Haque SJ. PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells. Oncogene 2005, 24:7290-7300. 10.1038/sj.onc.1208894, 16007122.
47. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000, 25:55-57. 10.1038/75596, 10802656.
48. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998, 95:15587-15591. 10.1073/pnas.95.26.15587, 28087, 9861013.